Literature DB >> 25381394

DPYD variants to predict 5-FU toxicity: the ultimate proof.

Federico Innocenti1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25381394     DOI: 10.1093/jnci/dju351

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  5 in total

Review 1.  The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines.

Authors:  Elena De Mattia; Rossana Roncato; Chiara Dalle Fratte; Fabrizio Ecca; Giuseppe Toffoli; Erika Cecchin
Journal:  Cancer Drug Resist       Date:  2019-03-19

Review 2.  Beyond BRCA: A Pilot Program to Assess and Improve Knowledge of Pharmacogenomic Testing Among Advanced Practitioners in a Breast Cancer Treatment Setting.

Authors:  Samuel L Hoffman; Robert Reid Reid Kaufman; Shannon Ferrari; Sheila Ann Alexander; Margaret Quinn Rosenzweig; Susan W Wesmiller
Journal:  J Adv Pract Oncol       Date:  2016-05-01

Review 3.  Bringing a genomic perspective to the safety of drug treatment in oncology.

Authors:  Federico Innocenti
Journal:  F1000Res       Date:  2017-03-29

4.  All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide.

Authors:  Federico Innocenti; Sarah C Mills; Hanna Sanoff; Joseph Ciccolini; Heinz-Josef Lenz; Gerard Milano
Journal:  JCO Oncol Pract       Date:  2020-11-16

5.  Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients.

Authors:  Marzia Del Re; Angela Michelucci; Angelo Di Leo; Maurizio Cantore; Roberto Bordonaro; Paolo Simi; Romano Danesi
Journal:  EPMA J       Date:  2015-09-02       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.